PharmaGap cancer drug proves effective

PharmaGap Inc. lead drug candidate is shown in lab trials to help increase by about 50% the efficacy of a cancer cell killing drug commonly used in chemotherapy. It was also proven to reduce patients’ exposure to toxic chemotherapy regimens, even for highly drug-resistant cancer cell lines such as those used while testing the drug. “[The lab studies] provide a strong rationale for the further preclinical assessment of this agent at Memorial Sloan-Kettering, with the hope of translating these studies into human clinical trials,” says Dr. Gary Schwartz, who directed the testing of the drug at Memorial Sloan-Kettering Cancer Center in New York City.” Earlier this month, PharmaGap raised $550,000 in a private placement deal with Dundee Securities.

Submit a comment

Please leave your name, which will be used to sign your submission to the SCANsite. Thanks for contributing your thoughts. Come back again. Tony Patterson, Editor & CEO.

© 2006 - 2009 SCAN
INTEGRITY INTELLIGENCE INFORMATION
Site by Citadel Rock
SCAN